nicorandil / Generic mfg. - LARVOL DELTA

Nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a meta-analysis. (PubMed, Future Cardiol) - "Nicorandil has promising efficacy and safety in reducing the risk of CIN. However, further trials are necessary in order to validate our conclusions."

Journal • Retrospective data • Review • Nephrology • Renal Disease • CST3

Role of nicorandil in preventing contrast-induced nephropathy in patients undergoing cardiac catheterization procedures: an updated systematic review and meta-analysis. (PubMed, Int Urol Nephrol) - "Nicorandil administration reduces the CIN incidence and improves renal biomarkers in patients undergoing CAG and PCI. Large-scale trials with longer follow-up periods are warranted to confirm renoprotective effects of nicorandil."

Journal • Retrospective data • Review • Renal Disease • CST3

Coronary microcirculation dysfunction causing ischemia with non-obstructive coronary arteries: a case report. (PubMed, Front Cardiovasc Med) - "After six months of targeted treatment with nicorandil, coenzyme Q10, trimetazidine, and rosuvastatin, the patient's symptoms resolved, and myocardial ischemia reversed. The NOTCH1 gene may play a potential role in INOCA caused by CMVD, however, further research is needed to elucidate its underlying regulatory mechanisms. The findings provide a foundation for precise diagnosis and personalized management of INOCA."

Journal • Cardiomyopathy • Cardiovascular • Myocardial Ischemia • MYH7 • NOTCH1

Anesthetic management of coronary artery reconstruction in a patient with myocardial ischemia caused by an anomalous origin of the right coronary artery running between the great vessels: a case report. (PubMed, JA Clin Rep) - "Targeted pharmacologic blood pressure control and multimodal monitoring are vital for safe perioperative outcomes in anomalous coronary artery origin cases."

Journal • Anesthesia • Cardiovascular • Hypertension • Myocardial Infarction • Myocardial Ischemia • Pain

Drug challenge test for early symptom control in patients with coronary artery spasm: a case report. (PubMed, Eur Heart J Case Rep) - "The combination of calcium channel blocker and nicorandil was not effective in mitigating her symptoms. Four potential symptom relief drugs-trimetazidine, shigyakusan, keishibukuryogan, and denopamine-were prescribed...Her symptoms were well controlled thereafter. The drug challenge test, which involves prescribing various types of drugs for short durations to evaluate their effects, may be an effective option for quickly controlling symptoms in patients with refractory CAS who exhibit frequent symptoms."

Journal • Cardiovascular • Pain

High altitude on cardiovascular system and its prevention study (ChiCTR) - P=N/A | N=3376 | Not yet recruiting | Sponsor: People's Hospital of Xizang Autonomous Region; People's Hospital of Xizang Autonomous Region

New trial • Cardiovascular • Coronary Artery Disease • Heart Failure • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

The effect of nicorandil compared to placebo on cardiac outcomes of patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis. (PubMed, Postepy Kardiol Interwencyjnej) - "Other clinical outcomes such as chest pain, cardiovascular death, and heart failure showed no significant effect of nicorandil treatment during the PCI procedure. Intracoronary nicorandil treatment during PCI in STEMI patients can significantly impact several important clinical outcomes, such as arrhythmia, coronary blood flow rate, and re-hospitalization incidence, but does not show significant effects on chest pain, cardiovascular death, and heart failure."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Pain

EFFICACY OF NICORANDIL IN PATIENTS WITH ST-SEGMENT ELEVATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: A SYSTEMATIC REVIEW AND META-ANALYSIS - Jawad Basit (ACC 2025) - "Nicorandil can reduce the risk of myocardial injury in this patient population."

Retrospective data • Review • Cardiovascular • Myocardial Infarction

EFFICACY OF NICORANDIL IN PREVENTING CONTRAST-INDUCED NEPHROPATHY AFTER CARDIAC CATHETERIZATION: SYSTEMATIC REVIEW AND META-ANALYSIS - Yousef Alsmairat (ACC 2025) - "This meta-analysis highlights the beneficial effect of nicorandil on the prevention of CIN in patients undergoing cardiac catheterization, particularly among those with CKD. However, no significant reduction in short-term mortality was found."

Retrospective data • Review • Chronic Kidney Disease • Nephrology • Renal Disease

THREE-YEAR CLINICAL OUTCOME OF FFR-GUIDED STRATEGY USING NICORANDIL VERSUS ATP - Yuki Numajiri (ACC 2025) - "Nicorandil was a safe, simple alternative to ATP in FFR evaluation, with similar clinical outcomes."

Clinical • Clinical data • Cardiovascular • Myocardial Infarction

EFFECT OF INTRAVENOUS NICORANDIL THERAPY ON MYOCARDIAL FUNCTION IN STEMI PATIENTS UNDERGOING PRIMARY PCI: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS - Taimurzeb Durrani (ACC 2025) - "Periprocedural nicorandil significantly reduced infarct size and LVESV while increasing LVEF in STEMI patients undergoing primary PCI. Future prospective studies are needed to corroborate these findings."

Retrospective data • Cardiovascular • Myocardial Infarction • Reperfusion Injury

Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial. (PubMed, Circ Cardiovasc Interv) - P4 | "Larger hypothesis-testing trials are warranted. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04310995."

Journal

Nicorandil repurposing in orofacial pain: preclinical findings in adult zebrafish. (PubMed, ChemMedChem) - "In contrast, the antinociceptive effect of nicorandil on menthol-induced nociception was not affected by a TRPM8 antagonist, suggesting that TRPM8 modulation is not involved in nicorandil's mechanism of action. The study highlights the potential of nicorandil as an analgesic through its interaction with TRPV1 and TRPA1 channels, providing a molecular basis for repositioning nicorandil as an effective analgesic drug."

Journal • Preclinical • Pain • TRPM8

Congenital long QT syndrome caused by a KCNH2 pathogenic variant exhibiting "motor seizures": a case report and literature review. (PubMed, BMC Pediatr) - "Following confirmation, the patient was initiated on long-term oral therapy with propranolol and nicorandil. When VEEG shows a "slow-flat-slow" pattern, differentiation from A-S syndrome caused by malignant arrhythmias is critical. Once cLQTS is diagnosed, it is imperative to initiate prompt and aggressive treatment to mitigate the risks of syncope and sudden cardiac death."

Journal • Review • Cardiovascular • CNS Disorders • Epilepsy • Ophthalmology • Strabismus • Urinary Incontinence • Urology • KCNH2

A study on the molecular mechanism of cardiac protection of procarboxylpeptidase in MIRI rats based on the NLRP3 signaling pathway. (PubMed, Sci Prog) - "Myocardial apoptosis index, myocardial infarction size, ejection fraction, and short axis shortening rate were significantly increased (P < 0.05). At the same time, PRCP and nicorandil therapy could reverse the damage effect caused by MIRI (P < 0.05).ConclusionPRCP can lessen MIRI and protect cardiac function in rats by inhibiting NLRP3/Capase-1/IL-18/IL-1β signaling pathway-mediated cell pyroptosis."

Journal • Preclinical • Cardiovascular • Inflammation • Myocardial Infarction • Myocardial Ischemia • Reperfusion Injury • IL18 • IL1B • NLRP3 • PRCP

Successful resolution of ST-segment elevation by intracoronary nicorandil administration during perfusion balloon inflation. (PubMed, Cardiovasc Interv Ther) - No abstract available

Journal

CLEAN: Clinical Efficacy and SAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention (clinicaltrials.gov) - P4 | N=1500 | Completed | Sponsor: Fudan University | Recruiting ➔ Completed | Trial primary completion date: Aug 2024 ➔ Dec 2024

Trial completion • Trial primary completion date • Cardiovascular • Myocardial Infarction

Improvement of coronary microcirculation in acute myocardial ischemia rats using a nanoscale carrier SiO2@PEG loaded with Nicorandil. (PubMed, Drug Deliv Transl Res) - "Taken together, SiO2@PEG-Nicorandil had exhibited superior cardiac-targeting capabilities and sustained-release properties. Within a specific concentration range, it demonstrated enhanced therapeutic effects in the treatment of coronary microcirculation disorders in rats when compared to conventional Nicorandil formulations."

Journal • Preclinical • Cardiovascular • Myocardial Infarction • Myocardial Ischemia • Thrombosis

Linking KATP channel activation to p-AKT/mTORC1/eEF2/BDNF axis unravels nicorandil's promise in countering acetaminophen-induced hepatic encephalopathy in mice. (PubMed, Life Sci) - "Forty-eight mice were randomly subdivided into four groups: control (saline), APAP model (1 g/kg, i.p.), NIC treatment (15 mg/kg/day p.o. for 14 days), and glibenclamide (GLIB "KATP blocker", 5 mg/kg/day, p.o. 1 h before NIC for 14 days). All these effects were abolished by GLIB pre-treatment, indicating the crucial role of KATP channel. Accordingly, NIC could alleviate APAP-induced liver injury and HE mainly dependent on KATP channel opening, with resultant inhibition of glutamate signaling, activation of p-AKT/mTORC1/eEF2/BDNF trajectory, and abating hippocampal inflammation."

Journal • Preclinical • CNS Disorders • Cognitive Disorders • Hepatic Encephalopathy • Hepatology • Liver Failure • Oncology • BDNF • TNFA

Efficacy and safety of nicorandil for prevention of contrast-induced nephropathy in patients undergoing coronary procedures: a systematic review and meta-analysis. (PubMed, Int Urol Nephrol) - "This meta-analysis concludes that nicorandil reduces CIN incidence after PCI or CAG without significantly increasing major adverse events. However, further well-designed, large-scale RCTs are needed to strengthen the practical relevance before routine clinical use."

Journal • Retrospective data • Review • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Nephrology • Renal Disease

Case report: venoarterial extracorporeal membrane oxygenation supported severe coronary vasospasm with recurrent cardiac arrest. (PubMed, Eur Heart J Case Rep) - "Long-acting vasodilators (molsidomine, nicorandil), alongside less commonly used treatments (magnesium, fluvastatin), may be useful in patients with refractory vasospasm. Lastly, it seems reasonable to consider transient stellate ganglion ablation and thoracic sympathectomy as the final step of treatment if severe episodes persist. Nevertheless, stronger evidence is needed for the aforementioned strategies."

Journal • Atherosclerosis • Cardiovascular

Nicorandil-induced Isolated Abducens Nerve Palsy: A Case Report. (PubMed, Intern Med) - "The patient recovered immediately after the discontinuation of nicorandil treatment. In cases of cranial nerve palsy after the initiation of nicorandil treatment, consideration of the involvement of nicorandil is necessary."

Journal • Cardiovascular • Pain

A Randomized Controlled Study on the Clinical Efficacy of Ginkgo Biloba Combined with Nicorandil in Patients with HFmrEF. (PubMed, Int Heart J) - "There was no statistically significant difference between the two groups of patients (P > 0.05) in the incidence of hypotension, hypoglycemia, hypokalemia, headache, and hospitalization due to worsening heart failure.Ginkgo biloba combined with Nicorandil can effectively improve heart function, blood lipid levels, blood glucose levels, renal function, exercise tolerance, and health-related quality of life in patients with HFmrEF. Because there were no significant adverse reactions, they can be safely used."

Clinical • Journal • Atrial Fibrillation • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Hypertension • Hypoglycemia • Hypotension • Metabolic Disorders • Pain

Effects of Fisetin and Nicorandil on adjuvant-induced rheumatoid arthritis in rats: Emerging role of TLR4/NF-κB-induced Pyroptosis, Nrf-2/HO-1, and OPG/RANKL pathways. (PubMed, Cytokine) - "Our investigation uncovered the TLR4/NF-κB pyroptotic signaling, Nrf-2/HO-1, and OPG/RANKL pathways as novel mechanistic insights into the anti-rheumatoid potential of fisetin and/or NIC, with superiority of combination approach, providing a beacon of hope for RA patients in terms of optimizing treatment protocol effectiveness and patient outcomes."

Journal • Preclinical • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • NLRP3 • TLR4 • TNFSF11

ROLE OF ISCHEMIC PRECONDITIONING TO PREVENT ACUTE KIDNEY INJURY IN POST CABG SURGERIES (ISN-WCN 2025) - "The intraoperative factors are comprised of the hemodynamic effects of cardiopulmonary bypass (CPB) pump, cytokine and chemokine expression, inflammatory mechanisms, microscopic and macroscopic emboli, effects of aprotinin, and effects of the on-pump technique...Drug therapy with sulfonamide or nicorandil (preconditioning-blocking and preconditioning-mimetic medication, respectively)...In addition , we also conclude that RIPC performed with total duration of ischemia < 20minutes renders the best benefit. However , due to the major limitations of the small sample size and variations of the surgical procedures and basal characteristics of the participants in this study , our conslusions need to be further corroborated in future larger studies."

IO biomarker • Surgery • Acute Kidney Injury • Addiction (Opioid and Alcohol) • Anemia • Anesthesia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Coronary Artery Disease • Heart Failure • Hematological Disorders • Infectious Disease • Inflammation • Myocardial Infarction • Nephrology • Peripheral Arterial Disease • Renal Disease • Reperfusion Injury • Septic Shock • HMGB1 • IGFBP7 • TIMP2